Clinical Scorecard: Previous Antibiotic Use as a Predictor of Early and Extended Hematologic Toxicity and Outcomes in Acute B-Cell Leukemia Patients Undergoing CD19 CAR T-Cell Therapy

At a Glance

Key Highlights

• Prior exposure to high-frequency antibiotics (meropenem, teicoplanin, piperacillin, ceftazidime) is significantly associated with severe early and prolonged hematologic toxicity after CAR-T therapy.
• A novel antibiotic-based scoring model incorporating HF ABX exposure, tumor burden, and baseline hematologic/inflammatory markers predicts hematologic toxicity with higher specificity and sensitivity than the CAR-HEMATOTOX model.
• High-risk patients identified by the model show delayed hematopoietic recovery and significantly worse progression-free and overall survival.

Guideline-Based Recommendations

Diagnosis

• Assess prior antibiotic exposure, especially HF ABX, before CAR-T cell therapy.
• Evaluate baseline platelet count, hemoglobin, CRP, ferritin, LDH, and tumor burden to stratify hematologic toxicity risk.

Management

• Use the antibiotic-based score model to identify patients at high risk for severe hematologic toxicity.
• Consider close monitoring and supportive care for patients with high-risk scores (≥3).

Monitoring & Follow-up

• Monitor neutrophil, platelet, and hemoglobin levels closely during the first 6 months post CAR-T infusion.
• Track hematopoietic recovery to guide prognosis and further interventions.

Risks

• High-frequency antibiotic exposure prior to CAR-T therapy increases risk of severe neutropenia, thrombocytopenia, and anemia.
• Delayed hematopoietic recovery correlates with poorer progression-free and overall survival.

Patient & Prescribing Data

114 patients with R/R B-ALL receiving CD19 CAR-T therapy; external validation cohort of 21 patients

64.5% had prior antibiotic exposure; HF ABX exposure strongly predicted severe hematologic toxicity and worse clinical outcomes; model showed improved diagnostic accuracy over existing CAR-HEMATOTOX scoring.

Clinical Best Practices

• Incorporate prior antibiotic exposure history, especially HF ABX, into pre-CAR-T therapy risk assessment.
• Apply the antibiotic-based scoring model to stratify patients and tailor monitoring intensity.
• Recognize that patients with high-risk scores require vigilant hematologic monitoring and potentially early interventions to mitigate toxicity.
• Use hematopoietic recovery as a prognostic marker for survival outcomes post CAR-T therapy.

References

• EHA/EBMT grading for immune effector cell-associated hematotoxicity (ICAHT) 2023